IDEAYA Biosciences, Inc. 8-K

What Happened

• On April 8, 2026 (filed April 9, 2026), IDEAYA Biosciences announced a clinical collaboration agreement with AstraZeneca to evaluate IDEAYA’s investigational DLL3 TOP1 antibody‑drug conjugate IDE849 in combination with AstraZeneca’s Imfinzi® (durvalumab) in extensive‑stage small cell lung cancer (SCLC). IDEAYA will sponsor the combination study and AstraZeneca will supply Imfinzi.
• The study is part of IDEAYA’s ongoing multi‑site global Phase 1 program for IDE849 in DLL3‑upregulated solid tumors, which includes SCLC, neuroendocrine carcinomas (NECs), neuroendocrine tumors (NETs), and melanoma, with planned enrollment in North America, Europe, Australia, South America, and Asia.

Key Details

• Agreement date: April 8, 2026; 8‑K filed April 9, 2026.
• Drug combo: IDE849 (DLL3 TOP1 ADC) + Imfinzi (durvalumab, a PD‑L1 inhibitor).
• Sponsorship/supply: IDEAYA will sponsor the clinical combination study; AstraZeneca will supply Imfinzi.
• Trial scope: Multi‑site global Phase 1 trial; enrolling across multiple continents for DLL3‑upregulated solid tumors.

Why It Matters

• The collaboration formally establishes a sponsored combination study testing IDE849 with a marketed PD‑L1 inhibitor (Imfinzi), expanding IDEAYA’s clinical program for DLL3‑targeted therapy.
• For investors, this is a development milestone that could lead to combination‑therapy clinical data; the filing also includes standard forward‑looking statements and notes the usual risks of early‑stage clinical development (see IDEAYA’s Form 10‑K dated February 17, 2026 for additional risk factors).